GlassScriptPhysician profile
Jiten Mehta
NPI 1861912289
$1,437.66
in general payments reported to CMS, 2019-2025
15 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.02 · 2021: $110 · 2022: $213 · 2023: $355 · 2024: $322 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.22 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.14 | 2022-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $195.13 | 2023-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.34 | 2024 | Jardiance |
| Calliditas Therapeutics US INC. | $124.26 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $109.75 | 2021 | |
| Amgen INC. | $66.21 | 2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $55.83 | 2024 | |
| Opko Pharmaceuticals, LLC | $53.95 | 2022-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $30.02 | 2020 | |
| Fresenius USA Marketing, INC. | $27.50 | 2024 | Velphoro |
| Ardelyx, INC. | $23.49 | 2024 | Ibsrela |
| Lilly USA, LLC | $18.84 | 2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2024 | |
| Mallinckrodt Hospital Products INC. | $11.99 | 2022 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiten Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.